Accueil   Diary - News   All news BIOASTER and Pherecydes Pharma join forces to explore the use of phage therapy

BIOASTER and Pherecydes Pharma join forces to explore the use of phage therapy

 

July 9th, 2019 - BIOASTER, the French Technology Research Institute (TRI) for Microbiology and Infectious Diseases, announced today the signature of a collaboration agreement with Pherecydes Pharma, a French Biotechnology company, with the objective of discovering lytic bacteriophages, to be developed into a pharmaceutical solution to treat bacterial infections including those caused by multidrug resistant strains.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree